ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS
https://doi.org/10.14412/1995-4484-2011-1461
Abstract
Along with its basic activity in removing B-lymphocytes, rituximab (RTM) causes depletion of a population of CD20+ T cells that can pro- duce a variety of immunoregulatory and proinflammatory cytokines and chemokines.
Objective: to define a role of multiplex cytokine analysis in the evaluation of the efficiency of using RMT in rheumatoid arthritis (RA).
Subjects and methods. Thirty-four patients with the valid diagnosis of RA according to the ACR criteria of 1987 were examined. The con- centrations of cytokines were measured using the xMAP technology (27-plex).
Results and discussion. In the group of patients with a clinical response to therapy with the gene engineering biological agent, there was a decrease in the concentrations of interleukins (IL) 1β, 1ra, 2, 4, 6, 9, and 13, granulocyte macrophage colony-stimulating factor (GM- CSF), γ-interferon (IFN-γ), monocyte chemoattractant 1 at week 8 of therapy; that in IL 1β, 1ra, 2, 5, 6, 9, 10, 12, 13, and 15, fibroblast growth factor 2 (FGF-2), GM-CSF, IFN-γ, and tumor necrosis factor-α at week 24, and that in IL-9 at week 40. The no-clinical response group showed a reduction in GM-CSF at week 8 and in IL-2 and macrophage inflammatory protein 1β (MIP-1β) at week 40, and an increase in IL-8 at week 8. At week 8 after drug infusion, the elevated levels of IL-17 and MIP-1β can be identified as possible early pre- dictors of a response (at week 40). Comparison of the baseline cytokine levels in the groups with different clinical response demonstrated a more than three-fold increase in the concentrations of IL 4, 5, 7, 8, 10, 12, 13, 15, 17, IFN-γ, and vascular endothelial growth factor, and IL-8 at weeks 8 and 40, respectively.
About the Authors
A. A. Novikov
аleksandrovaen@irramn.ru
E. N. Aleksandrova
T. V. Popkova
O. G. Lineva
A. S. Avdeyeva
D. S. Novikova
G. Kh. Kuzikyants
G. V. Lukina
Ya. A. Sigidin
A. V. Karaulov
S. N. Bykovskaya
E. L. Nasonov
References
1. <div><p>Browning J.L. B cell move to centre stage: novel opportunities for autoimmune disease treatment. Nature Rev 2006;5:564-76.</p><p>Насонов Е.Л. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клин фармакол тер 2006;1-5:55-8.</p><p>Do rner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol 2006;77:3-11.</p><p>Wilk E., Witte T., Marquardt N. et al. Depletion of functionally active CD20- T cells by rituximab treatment. Arthr Rheum 2009;12(60):3563-71.</p><p>Yamamoto A., Sato К., Miyoshi F. et al. Analisis of cytokine production patterns of peripheriel blood mononuclear cells from a rheumatoid arthritis patient successfully treated witch rituximab. Mod Rheumatol 2010;2:183-7.</p><p>Brennan F., McInnes I. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118(11):3537-45.</p><p>Bansard C., Lequerre T., Daveau M. еt al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predictedRheumatology (Oxford) 2009;48(9): 1021-8.</p><p>Kingsmore S. Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov 2006;5(4):310-20.</p><p>Олюнин Ю.А. Оценка эффективности терапии ревматоидного артрита. Международные индексы оценки активности, функционального статуса и качества жизни больных ревматическими заболеваниями. М., 2007;3-12.</p><p>Blom M., Wenink M., Huijbens R. et al. Altered Circulating Cytokine Pattern after Administration of Rituximab is Correlated with Response to Therapy in Rheumatoid Arthritis. Arthr Rheum 2008;58(19):450.</p><p>Fabre S., Guisset C., Tatem L. et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009;155(3):395-402.</p><p>Thurling R.M., Boumans M.J.H., Vos K. et al. Early changes in serum levels of cytokines and chemokines are predictive of the response to Rituximab treatment in rheumatoid arthritis. Arthr Rheum 2009;60(Suppl.):630</p></div><br />
Review
For citations:
Novikov A.A., Aleksandrova E.N., Popkova T.V., Lineva O.G., Avdeyeva A.S., Novikova D.S., Kuzikyants G.Kh., Lukina G.V., Sigidin Ya.A., Karaulov A.V., Bykovskaya S.N., Nasonov E.L. ROLE OF MULTIPLEX CYTOKINE ANALYSIS IN THE EVALUATION OF THE EFFICACY OF RITUXIMAB DURING TREATMENT FOR RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2011;49(5):51-57. (In Russ.) https://doi.org/10.14412/1995-4484-2011-1461
Views:
1458
Email this article 